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Paul J. MartinIn allogeneic hematopoietic cell transplantation
(HCT), the benefit of graft-versus-leukemia (GVL)
effects often comes with the harm of graft-versus-
host disease (GVHD). In this issue of BBMT, Laport
et al. [1] map a possible path toward GVL with
a reduced risk of GVHD.
GVL effects in humans were originally docu-
mented in observational studies by showing that the
risk of recurrent malignancy was lower in patients
with acute or chronic GVHD (aGVHD, cGVHD)
compared with those without GVHD.Direct evidence
for the potency of GVL effects came from studies
showing that infusion of donor lymphocytes could
induce remission in patients with recurrent or persis-
tent malignancy after allogeneic HCT. The approach
of using donor lymphocyte infusions (DLI) to treat
recurrent malignancy after allogeneic HCT, however,
has several limitations. First, the procedure is most
effective for treatment of patients with chronic mye-
loid leukemia and is far less effective for treatment of
other diseases. Second, the procedure is most effective
when malignant cells cannot be detected and when the
disease is progressing slowly, while offering little or no
benefit when malignant cells can be detected or when
the disease is progressing rapidly. Third, the proce-
dure is often complicated by aGVHD or cGVHD
and sometimes by marrow aplasia.
Cytokine-induced killer (CIK) cells are a heteroge-
neous population of immune effector cells produced
by incubating blood leukocytes in medium containing
interferon-g, interleukin-2, and an activating CD3-
specific antibody for 21 to 28 days [2]. Laport et al.
[1] show that under culture conditions scaled for
clinical application under Good Manufacturing Prac-
tice, the number of T cells increased approximately
10-fold, and the number of natural killer (NK)-T cells
expressing both CD3 and CD56 increased approxi-Fred Hutchinson Cancer Research Center, University of
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product expressed CD3, and approximately half of
the cells also expressed NKG2D (CD314), a cell
surface molecule that functions as an activating recep-
tor for NK cells and a costimulatory receptor for T cell
activation. These CIK cells killed malignant cells
through mechanisms that did not require recognition
of peptide antigens presented by major histocompati-
bility molecules. Previous studies have shown that
CIK cells have minimal cytotoxic activity against
normal marrow cells or hematopoietic cells [3].
The phase I clinical trial by Laport et al. [1] was
designed to assess the feasibility of using CIK cells
from HLA-matched sibling donors to treat recurrent
malignancy after allogeneic HCT. Using a dose-
escalation design, they showed that CIK cells could
be given at doses as high as 1  108 per kg recipient
body weight without causing acute infusion-related
toxicity. Two of the 18 patients developed grade II
aGVHD, and 1 developed limited cGVHD. To put
these results in perspective, a previous study by Huff
et al. [4] showed that approximately 40% of patients
who are given conventional DLI from an HLA-
identical sibling donor develop grade II-IV aGVHD
or cGVHD. Results of that study did not show any
apparent relationship between the number of cells
infused and the risk of GVHD. Likewise, the study
by Laport et al. [1] did not show a relationship between
the number of cells infused and the risk of GVHD.
Approximately 20% of the patients in the study by
Huff et al. [4] had grade III or IV aGVHD, compared
with none in the study by Laport et al. [1]. Taken
together, these results suggest that the risk of
GVHD is lower with infusion of CIK cells compared
with conventional T cells.
Although the study by Laport et al. [1] was not
designed to assess efficacy, the results showed some en-
couraging hints. Seven patients hadmeasurable disease
when CIK cells were infused. Subsequent complete
remissions were documented in 3 of these patients,
1 with acute myeloid leukemia (AML), 1 with mye-
loma, and 1 with myelodysplastic syndrome (MDS).
The patient with AML had been previously treated
unsuccessfully with conventional DLI. The patient
with AML and the patient with myeloma subsequently
died with recurrent malignancy, but the patient with
MDS remained alive without detectable MDS at
3 months after infusion of CIK cells. In 5 patients,1571
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was longer than the duration of the initial remission
after HCT.
Although the available data suggest that the risk of
GVHD is reduced with CIK cells compared with
T cells, the efficacy of CIK cells compared with T cells
in mediating GVL effects remains to be determined.
Because the CIK population contained approximately
85% T cells and 15% NK-T cells, the apparent GVL
activity of CIK cells could be attributed to T cells as
opposed to NK-T cells. In a previous study, Introna
et al. [5] observed remissions in 3 of 11 patients who
were treated with infusion of CIK cells at a time
when malignant cells were detectable. In each of these
3 cases, the patient had been previously treated unsuc-
cessfully with conventional DLI. Successful remission
induction by infusion of CIK cells after unsuccessful
DLI suggests that the GVL activity of CIK cells was
attributable to NK-T cells rather than T cells,
although delayed effects of prior DLI cannot be
excluded in these cases.
The low risk of GVHD demonstrated in the study
by Laport et al. [1] now makes it reasonable to test
whether CIK cells could be administered preemptively
when the burden of malignant cells is at a nadir after
HCT to prevent recurrent malignancy, especially in
patients who have not previously had the benefit of
a GVL effect associated with aGVHD or cGVHD.
In addition, it would be of great interest to determine
whether administration of NK-T cells isolated from
the CIK population could decrease the risk of
GVHD even further, while enhancing cytotoxicactivity against diseases that typically do not respond
to conventional DLI. A final step in this possible
path toward GVL without GVHD would be to
decrease the complexity and costs of producing the
cells, so that the approach could be exported easily to
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